ArticleCureus2025
Capivasertib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient With Metastatic Prostate Cancer With Bone Involvement: A Case Report of a Rare but Serious Metabolic Complication.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring.Internal medicine (Tokyo, Japan) · 2026Article
- Capivasertib-Induced Diabetes Successfully Managed With Insulin-Independent Glucose-Lowering Agents: A Case Report.Cureus · 2026Article
- Capivasertib-Associated Diabetic Ketoacidosis With Concurrent Myocardial Injury in a Patient With Pre-Existing Coronary Artery Disease.Case reports in endocrinology · 2026Article
- Glycemic Derangements With Capivasertib-From Hyperglycemia to Diabetic Ketoacidosis: A Report of 3 Cases.JCEM case reports · 2025Article
- A Case of Grade 4 Hyperglycemia Induced by Capivasertib and Successfully Managed with Early Insulin Intervention.Surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capivasertib, a protein kinase B (AKT) inhibitor manufactured by AstraZeneca pharmaceutical and used in the treatment of various malignancies, has been implicated in cases of drug-induced diabetic ketoacidosis (DKA). We present a case of capivasertib-induced DKA in a patient with no prior history of diabetes, highlighting the metabolic complications associated with this targeted therapy. The proposed mechanism involves AKT inhibition leading to impaired insulin signaling, reduced glucose uptake, and increased lipolysis, ultimately resulting in ketogenesis. This case underscores the need for vigilant glucose monitoring in patients receiving capivasertib, especially those with predisposing risk factors for insulin resistance or pancreatic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.